Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) Meeting Abstract
| Authors: | Omuro, A. M.; Beal, K.; Karimi, S.; Chan, T. A.; Panageas, K.; Nayak, L.; Seko, B.; DeAngelis, L. M.; Abrey, L. E.; Gutin, P. H. |
| Abstract Title: | Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) |
| Meeting Title: | 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 28 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2010 Jun 4-8 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2010-05-20 |
| Start Page: | 188s |
| Language: | English |
| ACCESSION: | WOS:000208852003031 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2010.28.15_suppl.2036 |
| Notes: | Meeting Abstract: 2036 -- S -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
